June 18, 2026
6 mins read
Avience Biomedicals Limited is engaged in the healthcare diagnostics and medical devices segment, offering diagnostic kits, laboratory equipment, and related healthcare solutions. The Avience Biomedicals IPO opens on June 18, 2026, and closes on June 22, 2026. The issue comprises 14,53,800 equity shares aggregating up to ₹30.24 crore, with a price band of ₹196 to ₹208 per share. The shares are proposed to be listed on the NSE SME platform. This guide explains the IPO details, issue objectives, application process, share allocation, financial information, and other key aspects disclosed in the offer documents to help investors understand the offering.
Avience Biomedicals Limited operates in the healthcare diagnostics and medical devices segment, focusing on the manufacturing, supply, export, distribution, and trading of diagnostic products and equipment. The company serves a range of institutional customers, including pathology laboratories, microbiology laboratories, hospitals, and research centres. Its product portfolio covers rapid test kits, molecular diagnostic solutions, biochemistry analysers, reagents, haematology analysers, and selected medical devices used across healthcare settings. The company primarily caters to business-to-business (B2B) and business-to-government (B2G) markets. Over the years, the company has expanded its product offerings beyond diagnostic test kits to include a broader range of healthcare and laboratory solutions. Its manufacturing facility in Noida, Uttar Pradesh, supports its production activities, while its distribution and trading operations complement its product reach. By participating in multiple segments of the diagnostics and medical equipment value chain, the company has established a presence within the healthcare diagnostics ecosystem in India and selected overseas markets.
Investors can apply for the Avience Biomedicals Ltd IPO through the ASBA (Application Supported by Blocked Amount) process available via net banking platforms offered by eligible banks. Applicants need to log in to their banking portal, navigate to the IPO section, select the Avience Biomedicals Ltd IPO, enter the bid details, and submit the application. The application amount remains blocked in the bank account until the allotment process is completed. Alternatively, investors may apply through their registered stockbroker's online trading platform or mobile application. Applicants should ensure that their PAN, demat account, and bank account details are updated and linked appropriately before submitting the bid. After the application is submitted, investors can track the allotment status through the registrar's website and monitor subsequent listing-related updates through the relevant stock exchange platforms.
For more details, visit the Avience Biomedicals IPO page.
Details | Information |
IPO Date | June 18, 2026 to June 22, 2026 |
Issue Size | 14,53,800 shares (agg. up to ₹30.24 Cr) |
Price Band | ₹196 to ₹208 per share |
Lot Size | 600 shares |
Listing At | NSE SME |
Market Maker | Asnani Stock Broker Pvt. Ltd. |
Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
Funding the working capital requirement of the company
General corporate purposes
Event | Date |
|---|---|
IPO Open Date | Thu, Jun 18, 2026 |
IPO Close Date | Mon, Jun 22, 2026 |
Tentative Allotment | Tue, Jun 23, 2026 |
Initiation of Refunds | Wed, Jun 24, 2026 |
Credit of Shares to Demat | Wed, Jun 24, 2026 |
Tentative Listing Date | Thu, Jun 25, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Mon, Jun 22, 2026 |
₹196 to ₹208 per share
Application | Lots | Shares | Amount |
Individual investors (IND) (Min) | 2 | 1,200 | ₹2,49,600 |
Individual investors (IND) (Max) | 2 | 1,200 | ₹2,49,600 |
S-HNI (Min) | 3 | 1,800 | ₹3,74,400 |
S-HNI (Max) | 8 | 4,800 | ₹9,98,400 |
B-HNI (Min) | 9 | 5,400 | ₹11,23,200 |
The Avience Biomedicals IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the trading platform.
Go to the IPO section to view active IPO listings.
Locate Avience Biomedicals IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 600 shares) at the price band of ₹196 to ₹208 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Avience Biomedicals IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.
Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
QIB Shares Offered | 6,83,400 | 49.83% | 47.01% |
− Anchor Investor Shares Offered | 4,09,800 | - | 28.19% |
− QIB (Ex. Anchor) Shares Offered | 2,73,600 | - | 18.82% |
NII (HNI) Shares Offered | 2,07,000 | 15.09% | 14.24% |
− bNII > ₹10L | 1,38,000 | - | 9.49% |
− sNII < ₹10L | 69,000 | - | 4.75% |
Retail Shares Offered | 4,81,200 | 35.08% | 33.10% |
Firm Reservations | |||
Market Maker Shares Offered | 82,200 | - | 5.65% |
Total Shares Offered | 14,53,800 | 100.00% | 100.00% |
This structure reflects the allocation approach as disclosed in the issue documents, indicating the proportion of shares available to each investor category.
Total Assets: Grew from ₹34.65 crore in FY24 to ₹56.52 crore as of March 2025.
Total Income: Recorded at ₹45.97 crore in March 2025, as compared to ₹24.37 crore in FY24.
Profit After Tax (PAT): Reported at ₹7.23 crore in March 2025, and ₹2.14 crore in FY24.
Net Worth: Recorded at ₹22.78 crore in March 2025 compared to ₹6.21 crore in FY24.
Reserves & Surplus: Stood at ₹18.75 crore in March 2025, as compared to ₹2.93 crore in FY24.
Total Borrowings: Stood at ₹22.16 crore in March 2025, as compared to ₹15.13 crore in FY24.
EBITDA: Stood at ₹11.41 crore in March 2025 in comparison to ₹4.08 crore in FY24.
The company has reported growth in its asset base during the reviewed period, indicating an expansion of its operational footprint and business activities.
Total income increased compared to the previous financial year, reflecting higher business activity across the company's operations.
Profitability has improved during the period under review, supported by growth in business operations and earnings from core activities.
The company's net worth has strengthened, reflecting an increase in shareholders' funds and retained earnings.
Growth in reserves and surplus indicates the retention of profits within the business, which may support future operational and expansion-related requirements.
Operating performance has shown improvement, with earnings from business operations increasing over the reviewed period.
The company has continued to invest in its business and infrastructure, contributing to the expansion of its overall asset base.
Borrowings have increased alongside business growth, reflecting the utilisation of external funding to support operational and business requirements.
The company's diversified presence across diagnostic solutions, laboratory equipment, and medical devices provides exposure to multiple segments within the healthcare and diagnostics industry.
Ongoing participation in the healthcare diagnostics ecosystem and expansion of product offerings may support the company's operational development, subject to industry and market conditions.
The company has reported an increase in borrowings alongside the expansion of its operations. Future business performance may be influenced by its ability to manage debt obligations and funding requirements.
The business operates in the healthcare diagnostics and medical devices sector, which is subject to regulatory requirements, quality standards, and technological developments. Changes in regulations or industry practices may affect operations and compliance requirements.
The company operates across multiple segments of the healthcare diagnostics ecosystem, including diagnostic kits, molecular diagnostics, laboratory equipment, and medical devices, providing exposure to diverse end-user requirements.
A portion of the IPO proceeds is proposed to be utilised towards establishing a new manufacturing facility and supporting working capital requirements, which may contribute to operational expansion and capacity enhancement, subject to execution and business conditions.
Key Performance Indicator (KPI)
KPI | Jan 31, 2026 | Mar 31, 2025 |
ROE | 22.38% | 50.14% |
ROCE | 16.99% | 24.84% |
Debt/Equity | 0.94 | 0.97 |
RoNW | 22.38% | 49.89% |
PAT Margin | - | 15.86% |
EBITDA Margin | 24.70% | 25.22% |
Price to Book Value | 2.94 | 3.68 |
Registrar | Lead Manager(s) |
|---|---|
Skyline Financial Services Pvt. Ltd. | Fintellectual Corporate Advisors Pvt. Ltd. |
C-11, Block-C
Community Centre,
Janakpuri A-3,
Delhi, New Delhi, 110058
Phone: 1800-12-04-636
Email: info@avienbio.com
Website: https://avienbio.com/
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Avience Biomedicals IPO allotment status.
Dharam Deo Choudhary is the Promoter, Chairman, and Managing Director of the company.
The Avience Biomedicals IPO is scheduled to open for subscription on June 18, 2026, and close on June 22, 2026. Investors can submit their applications during this period through the ASBA facility offered by eligible banks or through their registered stockbrokers' trading platforms.
Avience Biomedicals Ltd operates in the healthcare diagnostics and medical devices segment. The company is engaged in the manufacturing, supply, export, distribution, and trading of diagnostic products and medical equipment. Its product portfolio includes diagnostic kits, molecular diagnostic solutions, laboratory analysers, reagents, and medical devices. The company serves institutional customers such as pathology laboratories, hospitals, research centres, and government entities. The long-term sustainability of the business may depend on factors such as industry demand, regulatory requirements, technological developments, operational execution, and market conditions.
The Avience Biomedicals IPO consists of 14,53,800 equity shares aggregating up to ₹30.24 crore. The shares are being offered within a price band of ₹196 to ₹208 per share and are proposed to be listed on the NSE SME platform.
The pre-apply facility allows investors to submit their IPO application before the issue opens for subscription. The application is generally processed once the IPO becomes available for bidding. Investors are required to complete the necessary payment authorisation through the applicable banking or UPI process within the prescribed timelines.
The lot size for the Avience Biomedicals IPO is 600 shares. Retail investors are required to apply for a minimum of two lots, which translates to 1,200 shares. Applications must be submitted in multiples of the prescribed lot size in accordance with the terms of the issue.
The tentative basis of allotment for the Avience Biomedicals IPO is scheduled for June 23, 2026. Following the allotment process, eligible applicants can check their allotment status through the registrar's website or other authorised channels.
Skyline Financial Services Private Limited has been appointed as the registrar to the Avience Biomedicals IPO. The registrar is responsible for processing IPO applications, finalising the basis of allotment, handling refunds where applicable, and facilitating the credit of allotted shares to investors' demat accounts.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
Investors can apply for the Avience Biomedicals IPO through the ASBA process available via eligible net banking platforms or through their registered stockbroker's online platform. The application process generally involves selecting the IPO, entering the desired quantity of shares, providing the required details, authorising the payment mandate, and submitting the application before the issue closes.
Yes, investors generally require an active demat account to apply for the Avience Biomedicals IPO. Shares allotted through the IPO process are credited electronically to the applicant's demat account. Applicants should ensure that their demat account details are accurate and linked to their application.
After the allotment process is completed, investors can check their application status through the registrar's website or the relevant stock exchange platforms. If shares are allotted, they will be credited to the investor's demat account. Applicants may also receive notifications from their broker, registrar, depository participant, or banking partner regarding the status of their application.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
|
Please Enter Mobile Number
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
|
